

STEVEN PHILIP SURYA

JKT, IDN • stevenphilip07@gmail.com



Citizenship / *Kewarganegaraan* Indonesia
Domicile / *Domisili* Jakarta

Education/ Pendidikan

- Master of Business Administration – Gadjah Mada University, Jakarta Campus, Indonesia
- Medical Doctor – Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
- Bachelor of Medicine – Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia

- Magister Administrasi Bisnis – Universitas Gadjah Mada, Kampus Jakarta, Indonesia
- Dokter – Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia
- Sarjana Kedokteran – Universitas Katolik Indonesia, Atma Jaya, Jakarta, Indonesia

License / lisensi

- Active member of Indonesia Health Council 2019 - now

- Anggota aktif Konsil Kedokteran Indonesia 2019 - sekarang

Working Experience / Pengalaman Kerja

PT Elektra Tekno Indonesia (2017 – now)

- Commissioners, 2022 – now
- Marketing Director, 2019-2022
- Marketing Manager, 2017 – 2019

PT MSD Indonesia (Subsidiary Merck & Co. Inc/ USA) (2025 – now)

- Commercial Operation, 2026 – now
- Senior Medical Science Liaison, 2025 – now

PT AstraZeneca Indonesia (subsidiary AstraZeneca plc/ England) (2023 – 2025)

- Medical Science Liaison, 2023 – 2025

PT Kalbe Genexine Biologics (joint venture: PT. Kalbe Farma, Tbk/ Indonesia, Genxine Inc./South Korea, and General Atlantic/ USA) (2022 – 2023)

- Medical Affairs and Clinical Trial Executive, 2022 – 2023

PT Elektra Tekno Indonesia (2017 – sekarang)

- Komisaris, 2022 – now
- Direktur Marketing, 2019-2022
- Manager Marketing, 2017 – 2019

PT MSD Indonesia (anak perusahaan Merck & Co. Inc/ USA) (2025 – now)

- *Commercial Operation*, 2026 – now
- *Senior Medical Science Liaison*, 2025 – now

PT AstraZeneca Indonesia (anak perusahaan AstraZeneca plc/ Inggris) (2023 – 2025)

- *Medical Science Liaison*, 2023 – 2025

PT Kalbe Genexine Biologics (*joint venture*: PT. Kalbe Farma, Tbk/ Indonesia, Genxine Inc./South Korea, and General Atlantic/ USA) (2022 – 2023)

- *Medical Affairs and Clinical Trial Executive*, 2022 – 2023